Related Experiment Video

Updated: Jul 6, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

The role and target potential of protein tyrosine phosphatases in cancer

Taolin Yi1, Daniel Lindner

  • 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, NB40, 9500 Euclid Avenue, Cleveland, OH 44195, USA. yit@ccf.org

Current Oncology Reports
|April 2, 2008
PubMed

Insights

Protein tyrosine phosphatases (PTPases) are crucial in cancer development and immune regulation. Targeting PTPases with small molecule inhibitors shows promise for novel cancer therapeutics and enhancing immunotherapy efficacy.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Protein tyrosine phosphatases (PTPases) play dual roles in cancer, acting as oncogenes or tumor suppressors.
  • PTPases are key regulators of cytokine and immune cell function, impacting cancer immunity.
  • Current cancer therapies, including immunotherapy, have limitations in response rates and survival benefits.

Purpose of the Study:

  • To explore PTPases as therapeutic targets for novel cancer treatments.
  • To investigate the potential of targeting PTPases to enhance immunotherapy efficacy.
  • To summarize the current state of PTPase-targeted cancer drug development.

Main Methods:

  • Review of literature on PTPase roles in oncogenesis and cancer immunity.
  • Analysis of preclinical data on selective PTPase inhibitors.
  • Examination of PTPase involvement in cytokine and immune cell signaling pathways.

Main Results:

  • Several PTPases are identified as oncogenic drivers or tumor suppressors in human cancers.
  • Targeting oncogenic PTPases with small molecule inhibitors demonstrates preclinical antitumor activity.
  • Inhibiting negative PTPase regulators may improve immunotherapy and cytokine therapy outcomes.
  • Selective PTPase inhibitors are advancing to early-phase clinical trials.

Conclusions:

  • PTPases represent a promising class of targets for developing innovative cancer therapeutics.
  • PTPase-targeted strategies hold potential for improving cancer treatment efficacy, including immunotherapy.
  • Continued research and development are expected to yield PTPase-targeted cancer drugs in the near future.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...